Teva to Present Data for AUSTEDO® XR (deutetrabenazine)

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® (fremanezumab) injectionPresentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when...

Related Keywords

Eric Hughes , Yael Ashman , Sanjeev Sharma , Teva Pharmaceutical Industries Ltd , Drug Administration , Teva Pharmaceuticals , Psych Congress On , Week Patient Titration Kit , Risperidone Subcutaneous Extended Release Study , Maintenance Treatment , Determining Clinician Factors , Defeating Barriers , Teva Pharmaceutical Industries , Psych Congress , Executive Vice President , Chief Medical Officer , Clinician Factors , Tardive Dyskinesia , Treatment Patterns , Deutetrabenazine When Initiated Using , Interim Results , Real World Effectiveness , Population Estimate , Patients With Tardive Dyskinesia , Real World Clinical Practice , Real World Antipsychotic , Vesicular Monoamine Transporter Type , Patients Newly Diagnosed With Tardive Dyskinesia , Without Deutetrabenazine , Exposure Response Analysis , Compare Changes , Clinical Endpoints , Huntington Disease Following Once Daily , Twice Daily Tablet Formulations , Cardiovascular Related Adverse Events , Patients With Schizophrenia Treated , Treatment With , Long Acting Subcutaneous Antipsychotic , Different Stages , Post Hoc Analysis , Schizophrenia Clinical Outcome Scenarios , Patient Provider Engagement , Schizophrenia Care , Long Term Safety , Patients With Schizophrenia , Local Tolerability , Injection Site Reactions , Initiating Long Acting Injectable Antipsychotics , Transitioning Patients , Long Acting Injectable Antipsychotics , Hypothetical Case , Results From , Placebo Controlled Safety , Efficacy Trial , Subcutaneous Use , Extended Release Injectable Suspension Use , Adults With Schizophrenia , Fremanezumab Treatment , Disability Outcomes , Major Depressive Disorder , Reducing Depression , Release Tablets , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Motor Impairment ,